

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Solute carrier family 31 copper transporters member 1 (SLC31A1; CTR1)	<p>Patient sample and mouse studies suggest that copper chelators could help increase the efficacy of platinum-based chemotherapy. In tumor samples from ovarian cancer patients, low levels of the copper transporter <i>CTR1</i> were associated with poor clinical response to platinum-based therapies. In a mouse model of human cervical cancer, the chelator tetrathiomolybdate plus the platinum chemotherapeutic cisplatin reduced tumor size and impaired angiogenesis compared with either agent alone. Next steps include testing the combination therapy in other mouse models of cancer.</p> <p>Cisplatin is a generic cancer drug.</p> <p>SciBX 3(25); doi:10.1038/scibx.2010.767 Published online June 24, 2010</p>	Findings unpatented; licensing status unknown	<p>Ishida, S. <i>et al. Cancer Cell</i>; published online June 14, 2010; doi:10.1016/j.ccr.2010.04.011</p> <p>Contact: Douglas Hanahan, University of California, San Francisco, Calif. e-mail: dh@ucsf.edu</p>